EBERS
Develops and manufactures advanced bioreactors and culture chambers for 3D cell culture and tissue engineering research, enabling precise mechanical and flow stimulation of scaffolds.
- CEO / Founder
- Pedro Moreo
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $2.9M
- Latest Round
- Grant
- Key Investors
- European Commission; SEPIDES E.P.E.; CDTI; EU NextGenerationEU / PRTR
Technology & Products
Key Products
EBERS specializes in advanced bioreactors for 3D cell culture and tissue engineering, including systems for mechanical and flow stimulation. They also offer CE-marked clinical devices for organ preservation, such as the ARK Kidney for renal and hepatic ex-situ normothermic perfusion.
Technological Advantage
Proprietary bioreactor designs that apply controlled flow rates and direct deformation to scaffolds, simulating in-vivo conditions; verified through academic collaborations and clinical certifications (CE mark under EU MDR 2017/745). Advantage is defensible through design expertise and regulatory approvals.
Differentiation
Value Proposition
Provides researchers with automated, customizable systems that replicate in-vivo mechanical and flow conditions, accelerating tissue engineering experiments and improving protocol reliability while reducing manual intervention.
How They Differentiate
Specializes in bioreactors for mechanical and flow stimulation in 3D cell culture, unlike general bioprinting hardware companies; offers CE-marked clinical devices for organ preservation, providing a regulatory edge in medical applications.
Market & Competition
Target Customers
Academic research institutions, biotechnology companies, and medical device developers in regenerative medicine and tissue engineering
Industry Verticals
Biotechnology; Medical Research; Regenerative Medicine; Tissue Engineering
Competitors
Paragonix Technologies, Organ Recovery Systems Inc., OrganOx Ltd.
Growth & Milestones
Growth Metrics
Awarded €2.57M H2020 SME-Phase II (NORMOPERF) for organ preservation device; CE-marked ARK Kidney under MDR (2023); June 2026 SEPIDES CVI grant €287k for human liver ex-vivo hepatotoxicity platform; further CDTI/PRTR R&D (Misión Salud, Multi-País 2024 with Jobst Technologies); global distributor network expanded.
Major Milestones
Founded 2009 as University of Zaragoza spin-off (Pedro Moreo CEO, Víctor Alastrué CTO); ISO13485; CE mark ARK Kidney® under EU MDR 2017/745 (Sep 2023); €2.57M H2020 SME-2 NORMOPERF (2018–2023); first clinical ARK Kidney transplant at Hospital Miguel Servet; SEPIDES CVI 2025 grant €287k (Jun 2026) for ex-vivo human liver drug-safety platform; CDTI Multi-País 2024 with Jobst Technologies.
Notable Customers
Hospital Universitario Miguel Servet (Zaragoza; first clinical ARK Kidney transplant trial site)